SHR BrcaReceptorStatusVS ValueSet

Classification of receptor status in breast cancer.

 <status value="draft" /> <date value="2017-12-20" /> <publisher value="The MITRE Corporation: Standard Health Record Collaborative" /> <contact> <telecom> <system value="url" /> <value value="http://standardhealthrecord.org" /> </telecom> </contact> <description value="Classification of receptor status in breast cancer." /> <compose> <include> <system value="http://standardhealthrecord.org/shr/oncology/cs/BrcaReceptorStatusCS" /> <concept> <code value="luminal_A" /> <display value="Group 1. Includes tumors that are ER positive and PR positive, but negative for HER2. Luminal A breast cancers are likely to benefit from hormone therapy and may also benefit from chemotherapy." /> </concept> <concept> <code value="luminal_B" /> <display value="Group 2. Includes tumors that are ER positive, PR negative and HER2 positive. Luminal B breast cancers are likely to benefit from chemotherapy and may benefit from hormone therapy and treatment targeted to HER2." /> </concept> <concept> <code value="HER2_positive" /> <display value="Group 3. Includes tumors that are ER negative and PR negative, but HER2 positive. HER2 breast cancers are likely to benefit from chemotherapy and treatment targeted to HER2." /> </concept> <concept> <code value="Triple_negative" /> <display value="Group 4. Also called basal-like breast cancer, includes tumors that are ER negative, PR negative and HER2 negative. Basal-like breast cancers are likely to benefit from chemotherapy." /> </concept> </include> </compose> </ValueSet>